For US Healthcare Professionals Only
A Sanofi Pasteur Company

Your shopping cart is empty
You are about to log out of

Would you like to place your order before you log out?

Log Out
Continue Shopping



Protects against all severities of pertussis 

  • DAPTACEL vaccine has demonstrated efficacy against laboratory-confirmed pertussis with as little as one day of cough in a rigorously designed, NIH*-sponsored pivotal trial (n=2587)1
    • 78% >1 day of cough
    • 85% >21 days of cough
  • The adverse reaction profile of DAPTACEL vaccine is comparable to that of the DT placebo 1

*NIH=National Institutes of Health.


DAPTACEL vaccine is indicated for active immunization against diphtheria, tetanus, and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to 7th birthday).

Safety Information
The most common local and systemic adverse reactions to DAPTACEL vaccine include injection site redness, swelling, and tenderness; fever, irritability, drowsiness, and crying more than usual. Other adverse reactions may occur. DAPTACEL vaccine is contraindicated in persons with a hypersensitivity to any component of the vaccine. In addition, it is contraindicated in persons with any immediate anaphylactic reaction or encephalopathy not attributable to another identifiable cause after a previous dose of DAPTACEL vaccine. Vaccination with DAPTACEL vaccine may not protect all individuals.

Before administering DAPTACEL vaccine, please see full prescribing information.

*DTaP = Diphtheria, tetanus, and acellular pertussis.

Reference: 1. Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a
two-component acellular, a five-component acellular, and a whole-cell pertussis
vaccine. N Engl J Med. 1996;334:349-355.




This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.